Author(s): Moree WJ, Kataoka K, RamirezWeinhouse MM, Shiota T, Imai M,
Abstract Share this page
Abstract Structure-activity relationships (SAR) of a weakly active class of CCR2b inhibitors were utilized to initiate a lead evolution program employing the Drug Discovery Engine. Several alternative structural series have been discovered that display nanomolar activity in the CCR2b binding and CCR2b-mediated chemotaxis assays.
This article was published in Bioorg Med Chem Lett
and referenced in Health Care : Current Reviews